Episode

Targeting Tumors from the Inside Out

Podcast
The Bio Report
Published
Jan 14, 2026
Duration seconds
1600
Processing state
not_requested
Canonical source
https://thebioreport.podbean.com/e/targeting-tumors-from-the-inside-out/
Audio
https://mcdn.podbean.com/mf/web/pzyhgv7tqthya27s/BR-Marc_Iacobucci-1-14-26adils.mp3
JSON
/v1/public/podcasts/the-bio-report-1092382/episodes/targeting-tumors-from-the-inside-out
Markdown
/podcast/the-bio-report-1092382/targeting-tumors-from-the-inside-out.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/the-bio-report-1092382/episodes/targeting-tumors-from-the-inside-out/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/the-bio-report-1092382/targeting-tumors-from-the-inside-out.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Systemic chemotherapy remains the foundation of cancer treatment, but its widespread toxicity too often cuts short potential therapeutic benefits. NanOlogy is developing a new approach—localized cancer therapy that keeps the drug where it’s needed most. We spoke to Marc Iacobucci, managing director of Nanology about the company’s precision particle engineering platform, how it transforms existing oncology drugs into microparticles optimized for intratumoral delivery; and how this enables sustained, high-concentration dosing inside tumors that destroys cancer cells, stimulates immune responses, and spares patients the debilitating effects of systemic chemotherapy.